XTRA Bitcoin Inc (CBTC)

[ALERTS100%to10000%GAIN]

TCEL~~Describe the Issuer’s Business, Products and Services
Describe the issuer’s business so a potential investor can clearly understand the company. In answering this item, please
include the following:
A. a description of the issuer’s business operations;
The Company’s business operations consist of doing business in the cell repair and cell replacement for Equine stock
only at present, but we are pursuing FDA approval for existing and modified products to be used for the repair of the
Human Body. It is estimated that this process will take up to six months assuming a problem-free time-line and funds
available to complete. Its products have been successfully utilised for the repair of horses tendons and have the
added bonus of being patented worldwide, with an exclusive licence in the name of the Company for equine and
human applications. In October 2013 we had to cease trialing the process due to lack of available and sustainable
funds. The new initiative to generate investment into the company will allow us to recommence these trials and move
towards selling the equine product on the open market. As a result, the Company is still in development and approval
stage.
Whilst we have raised the previosly estimated $2million required to obtain US Food and Drug Administration approval
of the patented process for humans and to make the product available to our targeted markets our due diligence has
been successfully completed and contracts now signed subject only to the remittance and clearance of funds. The
new loan investment in the Company will allow trials to recommence. The delay in receiving the new funding, due to
circumstances beyond our control or influence, has prevented us from pursuing the FDA approval, appointing our
preferred investor relations and public relations consultants and commissioning the new website.
B. Date and State (or Jurisdiction) of Incorporation:
OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v1.0 January 3, 2013) Page 9 of 11
05/20/2011 domiciled to the State of Wyoming
C. the issuer’s primary and secondary SIC Codes;
Primary SIC Code: 5094; Secondary SIC Code: None
D. the issuer’s fiscal year end date;
31st December
E. principal products or services, and their markets;
The Company’s principal product relates to existing patent licences held for cell repair and cell replacement of Equine
stock. The main markets for the current product are working and sporting horse stock.
7) Describe the Issuer’s Facilities
The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities
owned, used or leased by the issuer.
In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the
principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have
complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the
property), describe the limitations on the ownership.
If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.
None
8) Officers, Directors, and Control Persons
The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that
are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as
well as the identity of any significant shareholders.
A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each
of the issuer’s executive officers, directors, general partners and control persons (control persons are beneficial
owners of more than five percent (5%) of any class of the issuer’s equity securities), as of the date of this
information statement.
Susan Glover - Director
John Meredith - President, CEO, CFO/Treasurer

https://backend.otcmarkets.com/otcapi/company/financial-report/138904/content